An international research agenda for clozapine-resistant schizophrenia

Jurjen J. Luykx; Jairo M. Gonzalez-Diaz; Ta Wei Guu; Marte Z. van der Horst; Edwin van Dellen; Marco P. Boks; Sinan Guloksuz; Lynn E. DeLisi; Iris E. Sommer; Russel Cummins; David Shiers; Ahmed Mhalla; Zohra Chadly; Sherry K.W. Chan; Robert O. Cotes; Shun Takahashi; Michael E. Benros; Elias Wagner; Christoph U. Correll; Alkomiet Hasan; Dan Siskind; Dominique Endres; James MacCabe; Jari Tiihonen

doi:10.1016/S2215-0366(23)00109-8

An international research agenda for clozapine-resistant schizophrenia

Jurjen J. Luykx, Jairo M. Gonzalez-Diaz, Ta Wei Guu, Marte Z. van der Horst, Edwin van Dellen, Marco P. Boks, Sinan Guloksuz, Lynn E. DeLisi, Iris E. Sommer, Russel Cummins, David Shiers, Ahmed Mhalla, Zohra Chadly, Sherry K.W. Chan, Robert O. Cotes, Shun Takahashi, Michael E. Benros, Elias Wagner, Christoph U. Correll, Alkomiet HasanDan Siskind, Dominique Endres, James MacCabe, Jari Tiihonen

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.

Original language	English (US)
Pages (from-to)	644-652
Number of pages	9
Journal	The Lancet Psychiatry
Volume	10
Issue number	8
DOIs	https://doi.org/10.1016/S2215-0366(23)00109-8
State	Published - Aug 2023

All Science Journal Classification (ASJC) codes

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2215-0366(23)00109-8

Cite this

Luykx, J. J., Gonzalez-Diaz, J. M., Guu, T. W., van der Horst, M. Z., van Dellen, E., Boks, M. P., Guloksuz, S., DeLisi, L. E., Sommer, I. E., Cummins, R., Shiers, D., Mhalla, A., Chadly, Z., Chan, S. K. W., Cotes, R. O., Takahashi, S., Benros, M. E., Wagner, E., Correll, C. U., ... Tiihonen, J. (2023). An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry, 10(8), 644-652. https://doi.org/10.1016/S2215-0366(23)00109-8

@article{7a1ba30f734a4aac9efdc4cfa1faeb1c,

title = "An international research agenda for clozapine-resistant schizophrenia",

abstract = "Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.",

author = "Luykx, {Jurjen J.} and Gonzalez-Diaz, {Jairo M.} and Guu, {Ta Wei} and {van der Horst}, {Marte Z.} and {van Dellen}, Edwin and Boks, {Marco P.} and Sinan Guloksuz and DeLisi, {Lynn E.} and Sommer, {Iris E.} and Russel Cummins and David Shiers and Ahmed Mhalla and Zohra Chadly and Chan, {Sherry K.W.} and Cotes, {Robert O.} and Shun Takahashi and Benros, {Michael E.} and Elias Wagner and Correll, {Christoph U.} and Alkomiet Hasan and Dan Siskind and Dominique Endres and James MacCabe and Jari Tiihonen",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = aug,

doi = "10.1016/S2215-0366(23)00109-8",

language = "English (US)",

volume = "10",

pages = "644--652",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier Limited",

number = "8",

}

Luykx, JJ, Gonzalez-Diaz, JM, Guu, TW, van der Horst, MZ, van Dellen, E, Boks, MP, Guloksuz, S, DeLisi, LE, Sommer, IE, Cummins, R, Shiers, D, Mhalla, A, Chadly, Z, Chan, SKW, Cotes, RO, Takahashi, S, Benros, ME, Wagner, E, Correll, CU, Hasan, A, Siskind, D, Endres, D, MacCabe, J & Tiihonen, J 2023, 'An international research agenda for clozapine-resistant schizophrenia', The Lancet Psychiatry, vol. 10, no. 8, pp. 644-652. https://doi.org/10.1016/S2215-0366(23)00109-8

TY - JOUR

T1 - An international research agenda for clozapine-resistant schizophrenia

AU - Luykx, Jurjen J.

AU - Gonzalez-Diaz, Jairo M.

AU - Guu, Ta Wei

AU - van der Horst, Marte Z.

AU - van Dellen, Edwin

AU - Boks, Marco P.

AU - Guloksuz, Sinan

AU - DeLisi, Lynn E.

AU - Sommer, Iris E.

AU - Cummins, Russel

AU - Shiers, David

AU - Mhalla, Ahmed

AU - Chadly, Zohra

AU - Chan, Sherry K.W.

AU - Cotes, Robert O.

AU - Takahashi, Shun

AU - Benros, Michael E.

AU - Wagner, Elias

AU - Correll, Christoph U.

AU - Hasan, Alkomiet

AU - Siskind, Dan

AU - Endres, Dominique

AU - MacCabe, James

AU - Tiihonen, Jari

PY - 2023/8

Y1 - 2023/8

N2 - Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.

AB - Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85165341293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85165341293&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(23)00109-8

DO - 10.1016/S2215-0366(23)00109-8

M3 - Review article

C2 - 37329895

AN - SCOPUS:85165341293

SN - 2215-0366

VL - 10

SP - 644

EP - 652

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

IS - 8

ER -

An international research agenda for clozapine-resistant schizophrenia

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this